Literature DB >> 17921099

An update into the pathophysiological role of HER2 in cancer: therapeutic implications.

A Ocaña, A Pandiella.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17921099     DOI： 10.1007/s12094-007-0100-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  23 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

4.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

5.  NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.

Authors:  Miguel A Molina; Rosana Sáez; Elizabeth E Ramsey; María-José Garcia-Barchino; Federico Rojo; Adam J Evans; Joan Albanell; Edward J Keenan; Ana Lluch; Javier García-Conde; José Baselga; Gail M Clinton
Journal:  Clin Cancer Res       Date:  2002-02       Impact factor: 12.531

6.  Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.

Authors:  Javier A Menendez; Inderjit Mehmi; Ruth Lupu
Journal:  J Clin Oncol       Date:  2006-07-17       Impact factor: 44.544

7.  Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.

Authors:  Bin-Bing S Zhou; Michael Peyton; Biao He; Changnian Liu; Luc Girard; Eian Caudler; Yvonne Lo; Frederic Baribaud; Iwao Mikami; Noemi Reguart; Gengjie Yang; Yanlong Li; Wenqing Yao; Kris Vaddi; Adi F Gazdar; Steven M Friedman; David M Jablons; Robert C Newton; Jordan S Fridman; John D Minna; Peggy A Scherle
Journal:  Cancer Cell       Date:  2006-07       Impact factor: 31.743

8.  Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.

Authors:  Laura Yuste; Juan C Montero; Azucena Esparís-Ogando; Atanasio Pandiella
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

9.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

10.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.